North America exosome therapeutic market is projected to register a healthy CAGR of in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation:
North America Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of Administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Counties (U.S., Mexico).
Some of the major factors contributing to the growth of the market:
- Increasing prevalence of Lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases
- Increasing research and development

Market Players:

The key market players for North America exosome therapeutic market are listed below:
- evox THERAPEUTICS
- EXOCOBIO
- Exopharm
- AEGLE Therapeutics
- United Therapeutics Corporation
- Codiak BioSciences
- Jazz Pharmaceuticals, Inc.
- Boehringer Ingelheim International GmbH
- ReNeuron Group plc
- Capricor Therapeutics
- Avalon Globocare Corp.
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC.
- Stem Cells Group